- Home
- AQST vs LEO Comparison
AQST vs LEO Comparison
Compare AQST & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- LEO
- Stock Information
- Founded
- AQST 2004
- LEO 1987
- Country
- AQST United States
- LEO United States
- Employees
- AQST N/A
- LEO N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- LEO Trusts Except Educational Religious and Charitable
- Sector
- AQST Health Care
- LEO Finance
- Exchange
- AQST Nasdaq
- LEO Nasdaq
- Market Cap
- AQST 390.4M
- LEO 362.5M
- IPO Year
- AQST 2018
- LEO N/A
- Fundamental
- Price
- AQST $5.84
- LEO $6.23
- Analyst Decision
- AQST Strong Buy
- LEO
- Analyst Count
- AQST 7
- LEO 0
- Target Price
- AQST $10.29
- LEO N/A
- AVG Volume (30 Days)
- AQST 3.6M
- LEO 200.2K
- Earning Date
- AQST 11-03-2025
- LEO 01-01-0001
- Dividend Yield
- AQST N/A
- LEO 4.01%
- EPS Growth
- AQST N/A
- LEO N/A
- EPS
- AQST N/A
- LEO 0.04
- Revenue
- AQST $44,132,000.00
- LEO N/A
- Revenue This Year
- AQST N/A
- LEO N/A
- Revenue Next Year
- AQST $51.50
- LEO N/A
- P/E Ratio
- AQST N/A
- LEO $152.00
- Revenue Growth
- AQST N/A
- LEO N/A
- 52 Week Low
- AQST $2.12
- LEO $4.98
- 52 Week High
- AQST $6.43
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- AQST 62.29
- LEO 59.38
- Support Level
- AQST $5.47
- LEO $6.17
- Resistance Level
- AQST $5.93
- LEO $6.29
- Average True Range (ATR)
- AQST 0.36
- LEO 0.05
- MACD
- AQST 0.01
- LEO -0.01
- Stochastic Oscillator
- AQST 62.43
- LEO 45.83
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.